HPV/Cervical Cancer Screening: Comparative Effectiveness of Primary HPV-Based Testing versus Cytology
Journal of Advanced Scientific Research · 30.06.2026 · 17 (06) · 48-55
DOI: 10.55218/jasr.2026170606 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advanced Scientific Research, online erschienen am 30.06.2026. Verfasst von Goni Girija und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Background
Cervical cancer is a major preventable malignancy and in 2022, there were about 662,301 new cases and 348,874 deaths due tocervical cancer worldwide. In more than 99% of cases, the necessary cause is high-risk human papillomavirus (hrHPV). Cytology (Pap smear)screening has long been used and has proven effective, but its sensitivity has been identified as a limitation. HPV DNA-based primary screeninghas become a molecularly superior tool; however, synthesized evidence from randomized trials based on detection of CIN2+ data is limitedover the last 6 years (2022-2026).
Objectives
To systematically review and metaanalyse comparative performance of HPV-based primary screening compared to cervical cytologyfor detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+); to appraise HPV vaccination efficacy data; to evaluate self-samplingstrategies for under-screened populations; to evaluate emerging technologies such as AI-assisted colposcopy.
Methods
A systematic review and meta-analysis of peer-reviewed randomized controlled trials, systematic reviews and meta-analyses were carriedout between January 2022 and June 2026, in accordance with the guidelines of the PRISMA 2020 and the Cochrane guidelines. Databasesexplored were PubMed/MEDLINE, Embase, CENTRAL, Scopus and Web of Science. Primary outcome: detection rate for CIN2+ (RR, 95%CI). Secondary outcomes were HPV vaccination effectiveness, self-sampling uptake, test sensitivity/specificity, and cancer burden measures atthe population level.
Results
Across 8 RCTs encompassing 414,846 participants, HPV DNA-based screening detected CIN2+ lesions at a rate 61% higher thancytology (RR 1.61; 95% CI: 1.30–1.98; p < 0.00001). HPV mRNA testing was found to be equally sensitive (93.2% for CIN2+) but was morespecific (84.0%) than HPV DNA testing (80.8%). Of the 145 RCTs included in the meta-analysis, HPV vaccination was found to be effectivein decreasing the risk of developing CIN I by 85%, CIN II by 80%, and persistent HPV16/18 infection by 84%. The self-sampling strategiesresulted in 2.1–3.1-fold higher screening participation rates than standard care. The risk of cervical cancer was 2.78-fold higher for vulnerablepopulations (RR 2.78; 95% CI: 2.32–3.32). The deep learning colposcopy models had an AUC-ROC of 95.3%.
Conclusion
HPV-based primary screening is shown to be very clearly superior in terms of sensitivity for CIN2+ detection to cytology. TheWHO 90-70-90 elimination framework requires integrated vaccination, risk-stratified genotyping triage and self-sampling. AI-powered tools area game-changer in resource-constrained environments. There is an urgent need to address the disparities between high and low-HDI countries.
Zitieren
APA
Girija, G., & M, H. K. (2026). HPV/Cervical Cancer Screening: Comparative Effectiveness of Primary HPV-Based Testing versus Cytology. Journal of Advanced Scientific Research, 17(06), 48-55. https://doi.org/10.55218/jasr.2026170606
Vancouver
Girija G, M HK. HPV/Cervical Cancer Screening: Comparative Effectiveness of Primary HPV-Based Testing versus Cytology. Journal of Advanced Scientific Research. 2026;17(06):48-55. doi:10.55218/jasr.2026170606
BibTeX
@article{Girija2026,
author = {Girija, Goni and M, Harish K},
title = {HPV/Cervical Cancer Screening: Comparative Effectiveness of Primary HPV-Based Testing versus Cytology},
journal = {Journal of Advanced Scientific Research},
year = {2026},
volume = {17},
number = {06},
pages = {48--55},
doi = {10.55218/jasr.2026170606}
}
EUVIMED